The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Quiz|Articles|August 7, 2026
OncLive Weekly News Quiz (8/7/2026): Did You Catch This Week's Melanoma, Pancreatic, Breast, and Neuroendocrine Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, complete sentences, no repetitive openings).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; RP1) plus nivolumab (Opdivo) for adults with unresectable advanced cutaneous melanoma that progressed on anti–PD-1 therapy, based on the phase 1/2 IGNYTE trial (NCT03767348). What type of agent is RP1?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
4
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
5